Trials / Completed
CompletedNCT02669147
A Study to Determine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPC
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 160 (actual)
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · Academic / Other
- Sex
- Male
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective observational study to evaluate effectiveness and safety of Enzalutamide for Castration Resistant Prostate Cancer (CRPC) patients who decided to administer Enzalutamide after anti-androgen therapy. CRPC Patients who are observed PSA or disease progression after anti-androgen therapy and decided to administrate Enzalutamide will dose the Enzalutamide 160 mg orally once daily and observed the practical treatment. Total research term is for 4 years, consists of 2-year case registration terms and 2-year observational terms.
Conditions
Timeline
- Start date
- 2016-01-26
- Primary completion
- 2021-03-01
- Completion
- 2021-03-01
- First posted
- 2016-01-29
- Last updated
- 2022-12-28
Source: ClinicalTrials.gov record NCT02669147. Inclusion in this directory is not an endorsement.